Insulet (PODD) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.09 per share when it actually produced earnings of $0.08, delivering a surprise of -11.11%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Insulet, which belongs to the Zacks Medical – Products industry, posted revenues of $198 million for the quarter ended March 2020, surpassing the Zacks Consensus Estimate by 4.81%. This